• Bio-Path Holdings posted a net loss of USD 0.3 million, narrowing from a USD 2.9 million loss a year earlier; loss per share improved to USD 0.03 from USD 0.40.
• Revenue was unchanged at no revenue, while research and development expense fell to USD 0.1 million from USD 2 million on cash-flow constraints and a pause in BP1001 and BP1001-A clinical trials.
• General and administrative expense dropped to USD 0.3 million from USD 1.3 million on lower salaries and benefits tied to curtailed activities, including resignations and terminations.
• Cash was USD 0.1 million at March 31, 2026, and the company said it does not expect that balance to fund obligations for the next 12 months.
• The company said it instituted a company-wide operational pause in June 2025 to conserve capital, furloughing most employees while seeking financing, and noted its March 2025 Promissory Notes and April 2025 Promissory Note were in default as of March 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Path Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001663577-26-000156), on May 20, 2026, and is solely responsible for the information contained therein.